Abstracts tagged "Lupus"

Abstract Number: 1561 • 2019 ACR/ARP Annual Meeting
Decreased Nocturnal Blood Pressure Dipping in Patients with Systemic Lupus Erythematosus: Association with Markers of Inflammation
Daniel Carranza Leon¹, Annette Oeser ¹, Qiong Wu ¹, C. Michael Stein ², Michelle Ormseth ¹ and Cecilia Chung ², ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Blood pressure follows a circadian rhythm; usually systolic blood pressure (SBP) drops by more than 10% during the night. Absence of this phenomenon, known…
Abstract Number: 1786 • 2019 ACR/ARP Annual Meeting
Surrogate Pathways of Complement Activation in Novel Polygenic SLE-like Models of Kidney Injury
Sladjana Skopelja-Gardner¹, Xizhang Sun ², Yufeng Peng ², Lucrezia Colonna ², Payton Hermanson ², Lena Tanaka ², Joyce Tai ², David Salant ³ and Keith Elkon ², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle, ³Boston University, Boston
Background/Purpose: Lupus nephritis (LN) is a major contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Defective clearance of apoptotic cells (AC), autoantibodies, and…
Abstract Number: 2782 • 2019 ACR/ARP Annual Meeting
Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications
Daniel Li¹, Candace Feldman ¹, Hongshu Guan ¹, Brendan Everett ², Seoyoung C. Kim ³ and Karen Costenbader ², ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Human studies examining cardiovascular disease (CVD) risk associated with immunosuppressants (IS) have been limited, but mycophenolate mofetil (MMF) was shown to suppress vascular smooth muscle…
Abstract Number: 694 • 2019 ACR/ARP Annual Meeting
Body Mass Index at Time of Diagnosis Is Predictive of Future Disease Activity in SLE
George Stojan¹, Jessica Li ² and Michelle Petri ², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Obesity is more common in patients with SLE compared to the general population. The prevalence of obesity among SLE patients is between 28 and…
Abstract Number: 1568 • 2019 ACR/ARP Annual Meeting
High Risk Low Attenuation Non-Calcified Coronary Plaque in Lupus vs. Controls
George Stojan¹, Jessica Li ² and Michelle Petri ², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The presence of low attenuation noncalcified plaque (< 30 Haunsfield units) is one of the most characteristic vessel changes in unstable coronary plaques. Low-attenuation…
Abstract Number: 1828 • 2019 ACR/ARP Annual Meeting
Avascular Necrosis Is Associated with APOL1 Variants in African Americans with Systemic Lupus Erythematosus
Kevin Yip¹, Elizaveta Efuni ², Yingzhi Qian ¹, Robert Clancy ³, Jill Buyon ² and Ashira Blazer ¹, ¹New York University School of Medicine, New York City, ²New York University School of Medicine, New York, NY, ³New York University School of Medicine, New York
Background/Purpose: African Americans (AA) with systemic lupus erythematous (SLE) are at higher risk for both renal disease and avascular necrosis (AVN). The two Apolipoprotein L1…
Abstract Number: 2868 • 2019 ACR/ARP Annual Meeting
Baseline Clinical and Serological Findings in Pediatric-Onset Discoid Lupus Erythematosus: Analysis of a Multicenter Retrospective Cohort Study
Nnenna Ezeh¹, Kevin Buhr², Cordellia Nguyen³, Ohoud Al Ahmed⁴, Stacy Ardoin⁵, Virginia Barton⁶, Samantha Bell⁷, Heather Brandling-Bennett⁸, Leslie Castelo-Soccio⁹, Yvonne Chiu¹⁰, Benjamin Chong¹¹, Dominic Co¹², Irene Lara-Corrales¹³, Amber Cintosun¹³, Lucia Diaz¹⁴, Scott Andrew Elman¹⁵, Esteban Fernandez Faith⁴, Maria Teresa Garcia-Romero¹⁶, Julie Grossman-Kranseler⁸, Aimee Hersh¹⁷, Marcia Hogeling¹⁸, Andrew Hudson¹⁹, Raegan Hunt²⁰, Erin Ibler¹⁰, Mariana Marques²¹, Reesa Monir²², Vikash Oza²³, Amy Paller²⁴, Elana Putterman⁹, Pamela Rodriguez-Salgado¹⁶, Jennifer Schoch²², Allison Truong¹⁸, Jason Wang²³, Lara Wine Lee⁶, Ruth Ann Vleugels¹⁵, Marisa Klein-Gitelman²⁵, Emily von-Scheven²⁶, Victoria Werth²⁷, Kaveh Ardalan²⁸and Lisa Arkin²⁹,¹University of Wisconsin School of Medicine and Public Health, Madison, WI,²Department of Biostatistics & Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison,³University of Wisconsin School of Medicine and Public Health, Madison,⁴Department of Pediatrics, Division of Dermatology, Nationwide Children's Hospital/Ohio State University, Columbus,⁵Nationwide Children's Hospital, Columbus, OH,⁶Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston,⁷Department of Pediatrics, Division of Rheumatology, University of California at San Francisco, San Francisco,⁸Division of Dermatology; Department of Pediatrics, Seattle Children's Hospital/University of Washington School of Medicine, Seattle,⁹Department of Pediatrics, Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia,¹⁰Departments of Dermatology and Pediatrics, Medical College of Wisconsin, Milwaukee,¹¹University of Texas Southwestern, Dallas,¹²Department of Pediatrics, Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison,¹³Department of Pediatrics, Division of Dermatology, The Hospital for Sick Children/University of Toronto, Toronto, Canada,¹⁴Department of Pediatrics, Division of Dermatology, Dell Medical School/Dell Children's Hospital, Austin, Texas,¹⁵Department of Dermatology, Boston's Children Hospital/Harvard Medical School, Boston,¹⁶Department of Dermatology, National Institute for Pediatrics, Mexico City, Mexico,¹⁷University of Utah, Salt Lake City, UT,¹⁸Department of Dermatology, University of California at Los Angeles, Los Angeles,¹⁹Department of Dermatology, University of Texas Southwestern Medical Center, Dallas,²⁰Departments of Pediatrics and Dermatology, Texas Children's Hospital, Houston, Texas,²¹Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago,²²Department of Dermatology, University of Florida School of Medicine, Gainesville,²³Departments of Pediatrics and Dermatology, New York University School of Medicine, New York,²⁴Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago,²⁵Department of Pediatrics, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital, Chicago,²⁶University of California San Francisco, San Francisco,²⁷Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA,²⁸Division of Pediatric Rheumatology, Department of Pediatrics, Northwestern University, Chicago, Illinois,²⁹Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Background/Purpose: DLE is a rare, disfiguring disorder in children. Small retrospective studies suggest 20-25% of patients progress to SLE. Progression risk factors are poorly understood,…
Abstract Number: 695 • 2019 ACR/ARP Annual Meeting
Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis
George Stojan¹, Frank Curriero ², Anton Kvit ² and Michelle Petri ³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Understanding the role of environmental exposures in the development of SLE and their association with SLE activity may help identify modifiable risk factors and…
Abstract Number: 1583 • 2019 ACR/ARP Annual Meeting
Prognostic Value of Urinary Biomarkers for the Developing of End Stage Renal Disease in Patients with Systemic Lupus Erythematosus
Jose A Gómez-Puerta¹, Tomás Urrego ², Blanca Ortiz Reyes ³, Adriana Vanegas-García ⁴, Carlos H Muñoz-Vahos ⁴, Luis A González ⁴ and Gloria Vasquez ⁵, ¹Rheumatology Department, Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²Grupo de Inmunología Celular e Inmunogenética, Universidad de Antioquia, Medellín, Antioquia, Colombia, ³Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁴Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁵University of Antioquia, Medellin, Antioquia, Colombia
Background/Purpose: Background: There is an increasing knowledge about the utility of urinary biomarkers for the diagnosis of lupus nephritis (LN) in patients with systemic lupus…
Abstract Number: 1843 • 2019 ACR/ARP Annual Meeting
Predictors of Mortality Among Black Women with Systemic Lupus Erythematosus: The Black Women’s Experiences Living with Lupus (BeWELL) Study
Charmayne Dunlop-Thomas¹, Gaobin Bao ², Cristina Drenkard ², David Chae ³ and S Sam Lim ², ¹Emory University, Atlanta, Georgia, ²Emory University, Atlanta, GA, ³Auburn University, Auburn, AL
Background/Purpose: Mortality continues to be disproportionately high in Black women with SLE living in the South region of the United States. Recent studies suggest that…
Abstract Number: 2886 • 2019 ACR/ARP Annual Meeting
Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries
Emily Somers¹, Lu Wang ², W Joseph McCune ³, S Sam Lim ⁴, Cristina Drenkard ⁴, Elizabeth Ferucci ⁵, Maria Dall'Era ⁶, Caroline Gordon ⁷, Charles Helmick ⁸, Hilary Parton ⁹ and Peter Izmirly ¹⁰, ¹University of Michigan Schools of Medicine & Public Health, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann Arbor, MI, ⁴Emory University, Atlanta, GA, ⁵Alaska Native Tribal Health Consortium, Anchorage, AK, ⁶University of California, San Francisco, San Francisco, CA, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, ⁹New York City Department of Health & Mental Hygiene, Long Island City, NY, ¹⁰NYU School of Medicine, New York
Background/Purpose: The heterogeneity of the clinical manifestations of systemic lupus erythematosus (SLE) and lack of a diagnostic test make SLE difficult for epidemiologists to study.…
Abstract Number: 696 • 2019 ACR/ARP Annual Meeting
The Performance of a Renal Activity Index in Lupus Nephritis in Induction Therapy
Najla Aljaberi¹, Qing Ma ², Theresa Hennard ³, Arjun Mathur ⁴ and Hermine Brunner ⁵, ¹Divison of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Lupus nephritis (LN) is associated with high morbidity and mortality. Current standard tools to monitor LN are suboptimal compared to the invasive renal biopsy.…
Abstract Number: 1588 • 2019 ACR/ARP Annual Meeting
Disease Activity and Dysregulated Iron Metabolism: A Potentially Overlooked Mechanism for Anaemia in Patients with Systemic Lupus Erythematosus?
Chris Wincup¹, Thomas McDonnell ¹, George Robinson ¹, Filipa Farinha ¹, Anna Radziszewska ¹ and Anisur Rahman ¹, ¹University College London, London, United Kingdom
Background/Purpose: Haematological manifestations of SLE are common with anaemia reported in approximately 50% of cases, yet the role of altered iron metabolism is poorly understood.…
Abstract Number: 1849 • 2019 ACR/ARP Annual Meeting
Cost-related Prescription Non-adherence Is Associated with Patient-reported Outcomes of Systemic Lupus Erythematosus Activity and Damage: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Deeba Minhas¹, Wendy Marder ², Sioban Harlow ³, Hanna Saltzman ³, Afton Hassett ³, Suzanna Zick ³, Lu Wang ³, Kamil Barbour ⁴, Charles Helmick ⁵, Caroline Gordon ⁶, W. Joseph McCune ¹ and Emily Somers ³, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, ³University of Michigan, Ann Arbor, ⁴Centers for Disease Control and Prevention, Atlanta, ⁵Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, ⁶University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Medication access and adherence play key roles in determining patient outcomes. We investigated whether cost-related non-adherence (CRNA) to prescription medications was associated with worse…
Abstract Number: 706 • 2019 ACR/ARP Annual Meeting
Neuronal BC RNAs: Systemic Lupus Erythematosus Autoantibodies Cause Dendritic Transport Impairments
ILHAM MUSLIMOV¹, ANNA IACOANGELI ², TAESUN EOM ³, ANNE RUIZ ³, MADISEN LEE ³, STACY STEPHENSON ³ and Ellen M Ginzler ⁴, ¹SUNY DOWNSTATE MEDICAL CENTER Center, BROOKLYN, NY, ²Tisch MS Research Center of New York, NEW YORK, NY, ³SUNY DOWNSTATE MEDICAL CENTER, BROOKLYN, NY, ⁴State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: In systemic lupus erythematosus (SLE), autoantibodies are often directed against nucleic acids or their binding proteins. Regulatory Brain-specific Cytoplasmic (BC) RNAs operate as translational…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.